Isotretinoin vs. Doxycycline for Rosacea: Comparing Effects on Skin Inflammation Markers
Both isotretinoin and doxycycline reduced inflammatory biomarkers in rosacea skin, but through different mechanisms.
Quick Facts
What This Study Found
Both isotretinoin and doxycycline effectively reduced cutaneous inflammatory biomarkers in rosacea, but through distinct biological pathways.
Key Numbers
40 participants. Doxycycline 100 mg vs isotretinoin 0.3 mg/kg daily. 4-month treatment. VEGF vessel count reduced with doxycycline (P=0.010). VEGF intensity reduced with both. LL-37/cathelicidin expression reduced.
How They Did This
Randomized, comparative, evaluator-blinded trial with immunohistochemistry at baseline and 4 months in 40 participants.
Why This Research Matters
Understanding how these drugs work at the molecular level helps dermatologists choose the best treatment for individual rosacea patients.
The Bigger Picture
By revealing distinct mechanisms, this study supports personalized rosacea treatment based on individual disease characteristics.
What This Study Doesn't Tell Us
Relatively small sample (40 patients). 4-month timeframe may not capture long-term effects or relapse patterns.
Questions This Raises
- ?Which drug is better for specific rosacea subtypes based on biomarker profiles?
- ?Do the different mechanisms predict different relapse rates?
Trust & Context
- Key Stat:
- 40 patients Randomized comparative trial with immunohistochemical analysis at baseline and 4 months
- Evidence Grade:
- Randomized comparative trial with objective biomarker outcomes — moderate evidence strength for a focused dermatology question.
- Study Age:
- Published in 2025, adding molecular-level data to rosacea treatment decisions.
- Original Title:
- A comparative exploration of immunohistochemical markers in patients with papulopustular rosacea undergoing treatment with oral isotretinoin versus doxycycline.
- Published In:
- International journal of dermatology, 64(3), 546-551 (2025)
- Authors:
- Picosse, Fabíola, Rocha, Marco Alexandre, Costa, Caroline Sousa, Enokihara, Milvia Maria Simões E Silva, Sanudo, Adriana, Bagatin, Ediléia
- Database ID:
- RPEP-13050
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Is isotretinoin effective for rosacea?
Yes — this study showed it reduces inflammatory biomarkers in rosacea skin, working through sebaceous gland suppression and toll-like receptor modulation.
How does doxycycline treat rosacea?
Doxycycline works primarily through anti-inflammatory mechanisms rather than its antibiotic properties, reducing skin inflammation markers in rosacea.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13050APA
Picosse, Fabíola; Rocha, Marco Alexandre; Costa, Caroline Sousa; Enokihara, Milvia Maria Simões E Silva; Sanudo, Adriana; Bagatin, Ediléia. (2025). A comparative exploration of immunohistochemical markers in patients with papulopustular rosacea undergoing treatment with oral isotretinoin versus doxycycline.. International journal of dermatology, 64(3), 546-551. https://doi.org/10.1111/ijd.17420
MLA
Picosse, Fabíola, et al. "A comparative exploration of immunohistochemical markers in patients with papulopustular rosacea undergoing treatment with oral isotretinoin versus doxycycline.." International journal of dermatology, 2025. https://doi.org/10.1111/ijd.17420
RethinkPeptides
RethinkPeptides Research Database. "A comparative exploration of immunohistochemical markers in ..." RPEP-13050. Retrieved from https://rethinkpeptides.com/research/picosse-2025-a-comparative-exploration-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.